• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 58
  • 19
  • 14
  • 10
  • 8
  • 6
  • 4
  • 3
  • 2
  • 1
  • 1
  • 1
  • 1
  • Tagged with
  • 146
  • 132
  • 27
  • 21
  • 19
  • 17
  • 16
  • 15
  • 14
  • 13
  • 12
  • 12
  • 12
  • 11
  • 10
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
11

Development of targeted nanomedicine for glioblastoma therapy

Setua, Sonali January 2014 (has links)
No description available.
12

Functional characterization of human cell cycle related kinase in glioblastoma carcinogenesis

Cheung, Yuen-ting., 張婉婷. January 2003 (has links)
published_or_final_version / abstract / toc / Molecular Biology / Master / Master of Philosophy
13

Expression et localisation de la connexine 43 dans le glioblastome : implication pour la thérapie génique

Carrondo Cottin, Sylvine 20 April 2018 (has links)
L’effet de proximité est essentiel à la réussite de la stratégie thymidine kinase (HSV-tk)/ganciclovir (GCV) dans le traitement du cancer. Cette propriété correspond au transfert de GCV phosphorylé des cellules tumorales HSV-tk+ vers les cellules tumorales HSV-tk–, et est essentiellement médiée par les jonctions gap (JGs) constituées de molécules de connexine (Cx). Une perte d’expression et/ou une localisation périnucléaire des connexines est souvent décrite dans les tumeurs, ce qui pourrait conduire, en théorie, à une diminution de l’efficacité du traitement HSV-tk/GCV. L’approche HSV-tk/GCV a été testée au cours d’essais cliniques pour le traitement du glioblastome bien que l’expression de la Cx43 (principal constituant des JGs dans les astrocytes) ne soit parfaitement définie. Au cours de mes travaux, l’expression de la Cx43, sa localisation et sa fonctionnalité ont été étudiées dans des lignées établies, des biopsies et des cultures primaires de glioblastome. Dans les trois lignées immortalisées de glioblastome étudiées, la Cx43 se retrouve essentiellement localisée dans les endosomes et les lysosomes comparativement aux cellules HeLa/Cx43 qui présentent une localisation membranaire de la Cx43. Des JGs ont été observées dans la lignée U87, mais très peu dans les lignées SKI-1 et U251. De façon surprenante, les lignées SKI-1 et U87 présentent une capacité jonctionnelle supérieure à celle des cellules HeLa/Cx43. De plus, un important effet de proximité a pu être mesuré dans les cellules SKI-1 et U87 suite au traitement par le GCV. L’utilisation d’un inhibiteur spécifique de la perméabilité des JGs a confirmé que l’effet de proximité induit dans ces lignées est principalement dû aux JGs. De plus, la transfection d’un mutant dominant négatif de la Cx43 ou de siARN spécifiques des ARNm de la Cx43 a permis d’identifier la Cx43 comme le principal constituant des JGs dans ces lignées de glioblastome. L’expression de la Cx43 a été mesurée sur soixante-quatorze biopsies de glioblastome. Si son expression est souvent plus faible que dans le tissu sain, seulement 23% des échantillons sont dépourvus de Cx43. Huit lignées primaires ont été dérivées de résections de patients, et sept d’entre elles expriment la Cx43, cependant à différents niveaux d’intensité. Quatre lignées démontrent une localisation cytoplasmique de la Cx43. Malgré la localisation cytoplasmique prédominante de la Cx43, ces cellules sont capables de communiquer entre elles efficacement comme l’essai de double marquage en cytométrie de flux l’a démontré. Un vecteur lentiviral contenant le gène HSV-tk a été construit afin de mener les tests d’effet de proximité. Il a ainsi été mis en évidence que quelle que soit la localisation de la Cx43, l’effet de proximité est significatif dans toutes les lignées exprimant la Cx43 et inexistant lorsque la Cx43 n’est pas présente. Ces résultats démontrent que la Cx43 est exprimée dans la majorité des glioblastomes. La Cx43 peut être exprimée dans les lignées établies et les lignées primaires de glioblastome au niveau de la membrane plasmique ou dans le cytoplasme. Cette localisation aberrante ne bloque pas le transfert intercellulaire de molécules, ce qui suggère que les rares JGs présentes à la surface sont hautement fonctionnelles. Ces résultats indiquent que l’approche HSV-tk/GCV est un candidat valable pour le traitement du glioblastome, contrairement à d’autres tumeurs pour lesquelles la perte d’expression de Cx est bien documentée. Il serait ainsi intéressant que l’expression de la Cx43 soit étudiée dans les biopsies utilisées lors du diagnostic et constitue ainsi un prérequis pour le recrutement des patients lors d’essais cliniques. / The bystander effect is essential to the success of the Herpes simplex virus thymidine kinase (HSV-tk)/ganciclovir (GCV) strategy for cancer therapy. It consists of the transfer of phosphorylated GCV from HSV-tk+ cells to neighboring HSV-tk- cells, and it is mainly mediated via gap junctions that are made up of connexin molecules (Cx). Down-regulation and/or perinuclear localization of Cxs are common in tumors, and in theory it should decrease the efficacy of the HSV-tk/GCV treatment. The HSV-tk/GCV approach has been tested in glioblastoma patients although the status of Cx43 expression (the Cx member expressed in astrocytes) is unclear in this tumor type. In this study, we have carefully evaluated the Cx43 expression, specific localization and functionality in glioblastoma cell lines, biopsies and primary glioblastoma cell cultures. In the glioblastoma cell lines studied (SKI-1, U251 and U87), Cx43 accumulated mainly in late endosomes and lysosomes as compared to HeLa/Cx43 transfected cells that displayed Cx43 at the cellular membrane. Gap junctions were observed in U87 cells, but very few or rare plaques were present at the surface of SKI-1 and U251 cells, respectively. Surprisingly, calcein, a dye commonly used to assess the functionality of gap junctions, was able to diffuse more efficiently within U87 and SKI-1 cells than in HeLa/Cx43 cells. Furthermore, a strong bystander effect was mediated by HSV-tk+ SKI-1 and U87 cells treated with GCV. The use of a specific inhibitor of gap junction permeability, confirmed that the bystander effect in these cell lines was mainly due to gap junctions. Moreover, transfection of a Cx43 dominant negative mutant and specific siRNA against Cx43 mRNA defined this Cx subtype as the major component of gap junctions in these glioblastoma cell lines. The level of Cx43 expression was next assessed in seventy-four glioblastoma biopsies. Cx43 expression was mainly lower than in normal tissue, but only 23% of the glioblastoma samples studied lacked Cx43 expression. Eight glioblastoma primary cultures were derived from surgical resection, and seven of them expressed Cx43, although at different levels. A cytoplasmic localization of Cx43 was also observed in four primary cultures. Despite this predominant intracellular accumulation of Cx43, cells were able to communicate in an efficient manner as demonstrated with a dye transfer assay. A lentiviral vector containing HSV-tk has been constructed and bystander effect experiments with these primary glioblastoma cells were carried out. We noticed that the bystander effect was significative in primary cells expressing Cx43 wherever the Cx43 was localized, and no bystander effect was detected in cells without Cx43 expression. Our results indicate that Cx43 is expressed in the majority of glioblastomas. Cx43 can be found in glioblastoma cell lines and primary cultures at the cell surface, but also in perinuclear areas. This aberrant localization of Cx43 did not prevent the diffusion of molecules, suggesting that the few gap junction plaques present in glioblastoma cells are highly functional. These results suggest that glioblastoma is a suitable candidate for the HSV-tk/GCV approach contrary to some other tumor types in which the lack of Cx has been well documented. According to these results, the level of Cx43 should be tested in patient biopsies used for diagnostics and considered for patient enrollment in clinical trials.
14

Development of a novel hTERTC27 based cancer: gene therapy

Gao, Yi, 高毅 January 2007 (has links)
published_or_final_version / abstract / Microbiology / Doctoral / Doctor of Philosophy
15

Estudo funcional de genes de reparo de DNA superexpressos em glioblastoma multiforme /

Sousa, Juliana Ferreira de. January 2015 (has links)
Orientador : Valeria Valente / Banca: Cleslei Fernando Zanelli / Banca: Ana Lúcia Fachin Saltoratto / Resumo: Os tumores cerebrais primários mais comuns são denominados gliomas. Eles são definidos patologicamente pela presença de características histológicas e imuno-histoquímicas que evidenciam diferenciação glial. De acordo com a suposta linhagem de origem, eles são classificados como astrocitomas, oligodendrogliomas ou ependimomas. Dentre eles, os astrocitomas são os mais comuns e agressivos. O tratamento atualmente utilizado inclui remoção cirúrgica seguida de quimioterapia com temozolamida (TMZ) e radioterapia, porém sua eficácia é muito baixa devido à alta resistência das células tumorais. Buscando encontrar genes associados com a elevada resistência dos astrocitomas, realizamos um estudo anterior de expressão gênica diferencial utilizando uma coleção de genes de reparo de DNA. Nesta análise foram identificados sete genes significantemente superexpressos em glioblastoma multiforme (GBM), o tipo mais agressivo de astrocitoma. Estes genes são: APEX1, BRCA2, BRIP1, EXO1, NEIL3, RAD54L e XRCC2. Através de RT-PCR quantitativo, avaliamos os níveis de expressão destes genes em um painel expandido de 54 casos clínicos de astrocitomas de diferentes graus de malignidade e em 5 linhagens celulares de GBM. Todos os genes analisados mostraram-se mais expressos nos astrocitomas, com exceção de RAD54L em amostras de astrocitoma de grau II. Além disso, a superexpressão dos 7 genes avaliada isoladamente não exerce influência direta na sobrevida dos pacientes. Evidenciou-se ainda a superexpressão mais acentuada de EXO1 e NEIL3, que foram selecionados para realização de ensaios funcionais de silenciamento, e avaliação do ciclo celular e taxas de apoptose/morte efetiva das células. Estes ensaios foram realizados com as linhagens celulares T98G e U138MG, que apresentaram maiores níveis de expressão destes genes. Nos ensaios funcionais, observamos que o silenciamento... / Abstract: Gliomas are the most common type of primary brain cancers. They are pathologically defined by the presence of histological and immunehistochemical characteristics that evidence glial differentiation. According to the hypothetical cell of origin they are classified in: astrocytomas, oligodendrogliomas and ependimomas. Among them, astrocytomas are the more common and aggressive type. The treatment currently used for GBM includes surgical resection of tumor followed by chemotherapy with temozolamide (TMZ) and radiotherapy, but this protocol is still insufficient due to the high resistance of cancer cells. Searching for repair genes associated with the high resistance of astrocytomas, we developed a previous study of differential gene expression using a collection of DNA repair genes. In this analysis, we identified seven genes significantly overexpressed in glioblastoma multiforme (GBM), namely: APEX1, BRCA2, BRIP1, EXO1, NEIL3, RAD54L and XRCC2. Using quantitative RT-PCR, we evaluated the expression of these genes in an expanded panel of samples with 54 clinical cases of different grade astrocytomas and five GBM cell lines. All genes showed expression significantly higher in astrocytomas, except RAD54L in grade II astrocytomas. Moreover, the overexpression of this 7 genes evaluated individually doesn't exert direct influence upon patient's survival rate. Remarkably, EXO1 and NEIL3 showed the higher fold changes and were chosen for functional silencing assays. This experiments were performed with T98G and U138MG cell lines that showed the higher expression levels among the GBM cell lines analyzed. In the functional assays, we observed that the silencing of EXO1 or NEIL3 doesn't induce changes in the apoptosis and cell death rates and doesn't change the distribution of cells in cycle. Beyond this, the silencing of this two genes doesn't sentisizes cells to ionizing radiation. / Mestre
16

Discovery and Application of Neoepitopes in an Oncolytic Rhabdovirus Vaccine Approach to Treat Glioblastoma Multiforme

Jilesen, Zachary Keavin 02 October 2019 (has links)
Glioblastoma multiforme is the most common and lethal primary brain tumour in adults. Its aggressive and invasive phenotype makes it resistant to current standards of care, with a patient median survival following treatment of only 14 months. Potent and safe therapeutics are necessary to improve patient prognosis. Globally, efforts are being made in immunotherapies to combat such deleterious tumours. Preliminary work in the Stojdl lab has developed a novel oncolytic virus platform for brain cancer therapy that is non-toxic and exhibits potent anti-tumour efficacy. This platform is based on the rhabdovirus Farmington, identified for its potent oncolytic properties and engineering malleability. Herein, we begin to show our capability to discover and vaccinate against immunogenic neoepitopes derived from a mouse cancer mutanome. Engineering Farmington virus to express neoepitopes, allows for robust tumour specific immune proliferation following a prime vaccination. Overcoming problems of targeting self-antigen and antigen loss variants, a multi-neoepitope vaccine, presented here, is one of many alternative approaches to help combat cancer resistance. Despite achieving robust anti-tumour immunity by vaccination, selectivity of the tumour microenvironment remains an enormous challenge. Cumulative efforts in immunotherapy research will help drive novel therapeutics, like Farmington, into clinic and, ultimately, improve patient’s prognosis and quality of life.
17

Evaluation of Concomitant Temozolomide Treatment in Glioblastoma Multiforme Patients in Two Canadian Tertiary Care Centers

Alnaami, Ibrahim 11 1900 (has links)
The study evaluated the survival of 364 glioblastoma multiforme (GBM) patients who received different modalities of treatment in two Canadian tertiary care centres. Retrospective and prospective databases were utilized to do a retrospective population based cohort study. The thesis question was among treated GBM patients in Edmonton and Halifax; does the survival rate differ with introduction of concomitant temozolomide and radiation therapy (RT) versus non concomitant treatment? Our results indicate that concomitant temozolomide with radiation therapy and surgery was associated with longer survival in comparison to radiation therapy with surgery. We also found that age; surgical resection and shorter time to radiation therapy are important factors for longer survival. / Clinical epidemiology
18

GATA4 Represses Formation of Glioblastoma Multiforme

Agnihotri, Sameer 20 August 2012 (has links)
The GATA transcription factors consist of six family members that bind the consensus DNA binding element W-GATA-R, and are poorly characterized in the central nervous system (CNS). In this thesis we identify GATA4 to be expressed in the neurons and glia of normal murine and human embryonic and adult CNS with significant loss in Glioblastoma Multiforme (GBM). GBM is the most common and lethal primary brain tumour and exhibits multiple molecular aberrations. Here we report that loss of the transcription factor GATA4, a negative regulator of normal astrocyte proliferation, is a driver in glioma formation and fulfills the hallmarks of a tumour suppressor gene. Although GATA4 was expressed in normal brain, loss of GATA4 was observed in GBM operative samples and was a negative survival prognostic marker. GATA4 loss occurred through promoter hypermethylation or novel somatic mutations. Loss of GATA4 in normal human astrocytes promoted high-grade astrocytoma formation, in cooperation with other relevant genetic alterations such as activated Ras or loss of TP53. Loss of GATA4 with activated Ras in normal astrocytes promoted a progenitor like phenotype, formation of neurospheres and the ability to differentiate into astrocytes, neurons and oligodendrocytes. Re-expression of GATA4 in human GBM cell lines, primary cultures and brain tumour initiating cells suppressed tumour growth in vitro and in vivo through direct activation of the cell cycle inhibitor P21CIP1, independent of TP53. Re-expression of GATA4 also conferred sensitivity of GBM cells to temozolomide, a DNA alkylating agent currently used in GBM therapy. This sensitivity was independent of MGMT, the DNA repair enzyme often implicated in temozolomide resistance. Instead GATA4 reduced expression of APNG, a DNA repair enzyme poorly characterized in GBM mediated temozolomide resistance. Identification and validation of GATA4 as a tumour suppressor gene and its downstream targets in GBM may yield promising novel therapeutic strategies.
19

In situ Proximity Ligation-­based Analysis Reveals Aberrant Dimerization and Activation of Epidermal Growth Factor Receptors Prevalent in Glioblastoma Multiforme

Gajadhar, Aaron 09 January 2012 (has links)
Aberrations in Epidermal Growth Factor Receptor (EGFR/ErbB1) signalling are the most common oncogenic stimuli in human glioblastoma multiforme (GBM). Interactions between mutant and wildtype ErbB family members in GBMs are of biological and potential therapeutic importance. In this thesis, we describe our work developing and optimizing a novel in situ proximity ligation assay (PLA) for dimerization and activation analysis of EGFR mutants prevalent in GBMs. Utilizing this novel in situ platform for EGFR dimerization analysis, we seek to systematically interrogate the dimerization capacity and activation status amongst EGFR and EGFR mutants. Our in vitro analysis using this platform demonstrates the aberrant homo-/hetero-dimeric properties of EGFRvIII and EGFRc958 mutants, the two most common mutants associated with EGFR amplification in GBMs. In addition, dimer phospho-activation status can be detected using in situ PLA with ≥ 16-fold sensitivity and ≥ 17-fold signal-to-noise than phospho-EGFR measurements currently undertaken with IHC or IF. These aberrant features are not overexpression dependent but appear independent of cellular expression levels, suggesting inherent properties of the mutant receptors. This EGFR dimerization/activation detection platform may also be useful for evaluating novel anti-EGFR therapeutics. Our data suggests that various EGFR monoclonal antibody therapies have unique dimerization blocking abilities and that certain mutant EGFR dimer configurations can evade blockage by anti-EGFR treatments. Furthermore, we report for the first time the detection of wt- and EGFRvIII dimerization in GBM specimens, in keeping with our prior cell line data, and a potential feature of prognostic or diagnostic value in GBMs harbouring them. Additionally, we demonstrate the utility of this platform for measuring pEGFR and total EGFR expression on tissue samples, which has not been efficacious to date with conventional antibody-mediated techniques. Results from this thesis may therefore provide novel insights into the interaction and activation characteristics of EGFR mutants prevalent in GBMs, as well as the efficacy of current anti-EGFR therapies to target these mutants. In summary, these findings demonstrate the successful application of a novel in situ EGFR molecular detection platform which may have clinical utility in diagnostic evaluation or stratification of GBM patient subgroups for prognosis and treatment. Furthermore, since PLA allows specimen assessment of not only expression and activation, but also dimerization, which is not evaluated by current IHC techniques, it will likely serve as a way to evaluate promising anti-EGFR strategies directed at preventing EGFR dimerization and activation.
20

GATA4 Represses Formation of Glioblastoma Multiforme

Agnihotri, Sameer 20 August 2012 (has links)
The GATA transcription factors consist of six family members that bind the consensus DNA binding element W-GATA-R, and are poorly characterized in the central nervous system (CNS). In this thesis we identify GATA4 to be expressed in the neurons and glia of normal murine and human embryonic and adult CNS with significant loss in Glioblastoma Multiforme (GBM). GBM is the most common and lethal primary brain tumour and exhibits multiple molecular aberrations. Here we report that loss of the transcription factor GATA4, a negative regulator of normal astrocyte proliferation, is a driver in glioma formation and fulfills the hallmarks of a tumour suppressor gene. Although GATA4 was expressed in normal brain, loss of GATA4 was observed in GBM operative samples and was a negative survival prognostic marker. GATA4 loss occurred through promoter hypermethylation or novel somatic mutations. Loss of GATA4 in normal human astrocytes promoted high-grade astrocytoma formation, in cooperation with other relevant genetic alterations such as activated Ras or loss of TP53. Loss of GATA4 with activated Ras in normal astrocytes promoted a progenitor like phenotype, formation of neurospheres and the ability to differentiate into astrocytes, neurons and oligodendrocytes. Re-expression of GATA4 in human GBM cell lines, primary cultures and brain tumour initiating cells suppressed tumour growth in vitro and in vivo through direct activation of the cell cycle inhibitor P21CIP1, independent of TP53. Re-expression of GATA4 also conferred sensitivity of GBM cells to temozolomide, a DNA alkylating agent currently used in GBM therapy. This sensitivity was independent of MGMT, the DNA repair enzyme often implicated in temozolomide resistance. Instead GATA4 reduced expression of APNG, a DNA repair enzyme poorly characterized in GBM mediated temozolomide resistance. Identification and validation of GATA4 as a tumour suppressor gene and its downstream targets in GBM may yield promising novel therapeutic strategies.

Page generated in 0.0672 seconds